Open AccessTargeted Delivery of Nanovaccine to Dendritic Cells via DC-Binding Peptides Induces Potent Antiviral Immunity in vivo
Author(s) -
Ying Lü,
Ze-Hui Liu,
Yingxiang Li,
Huiling Xu,
Weihuan Fang,
Fang He
Publication year - 2022
Publication title -
international journal of nanomedicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.245
H-Index - 128
eISSN - 1178-2013
pISSN - 1176-9114
DOI - 10.2147/ijn.s357462
Subject(s) - porcine circovirus , antigen , immune system , antigen presentation , virus like particle , adjuvant , dendritic cell , chemistry , microbiology and biotechnology , biology , t cell , virology , virus , biochemistry , recombinant dna , immunology , gene
Dendritic cell (DC) targeted antigen delivery is a promising strategy to enhance vaccine efficacy and delivery of therapeutics. Self-assembling peptide-based nanoparticles and virus-like particles (VLPs) have attracted extensive interest as non-replicating vectors for nanovaccine design, based on their unique properties, including molecular specificity, biodegradability and biocompatibility. DCs are specialized antigen-presenting cells involved in antigen capture, processing, and presentation to initiate adaptive immune responses. Using DC-specific ligands for targeted delivery of antigens to DCs may be utilized as a promising strategy to drive efficient and strong immune responses.